Consider using diffusion tensor imaging in geron phase I trial

American Journal of Neuroradiology

Volumn 30, Issue 7, 2009, Pages

  Patel, C B ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DIFFUSION TENSOR IMAGING; HUMAN; LETTER; MYELINATION; NONHUMAN; OLIGODENDROGLIA; SENSITIVITY AND SPECIFICITY; SPINAL CORD INJURY; STEM CELL TRANSPLANTATION;

CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; SPINAL CORD INJURIES; STEM CELL TRANSPLANTATION; STEM CELLS; SURGERY, COMPUTER-ASSISTED;

EID: 68549094252     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1632     Document Type: Letter

References (6)

1. Couzin J. Biotechnology: celebration and concern over U.S. trial of embryonic stem cells. Science 2009;323:568
2. Geron Corporation. Geron receives FDA clearance to begin world's first human clinical trial of embryonic stem cell-based therapy. Available at: http:// geron.com/grnopc1clearance/grnopc1-backgrounder.pdf. Accessed February 5, 2009
3. Herrera JJ, Chacko T, Narayana PA. Histological correlation of diffusion tensor imaging metrics in experimental spinal cord injury. J Neurosci Res 2008;86:443-447
4. Budde MT, Kim JH, Liang HF, et al. Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Res Med 2007;57:688-695
5. Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006;51:527-539
6. Féron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005;128:2951-2960